Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...

Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.

(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui ...

MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein (a), or Lp (a), ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Merck inked a $2 billion licensing deal with China’s Hengrui Pharma for exclusive rights to an experimental heart disease ...

Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

Big Pharma taps Chinese innovation again--this time for a potential blockbuster heart treatment targeting 1.4B people.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...